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Introduction
Extracorporeal membrane oxygenation (ECMO)
is a unique form of cardiopulmonary bypass which
has been in clinical use for 20 years. It has become
standard therapy in the management of neonatal
respiratory failure in the past decade, and is also
being used selectively in the support of
respiratory and cardiac failure in the paediatric
and adult populations. New applications are
constantly being evaluated, considerably
expanding the range of patient care that can be
provided in an intensive care unit. Depending
upon the vascular access and intent, extra-
corporeal life support may be called ECMO,
ECC02R (extracorporeal C02 removal), ECLA
(extracorporeal lung assist) and CPS (cardiopul-
monary support) - all are essentially synonymous.
ECMO has brought the technology of cardiopul-
monary bypass to the bedside under the
management of intensive care physicians and
ECMO specialists. A brief description of the
technique of ECMO support follows, in which
similarities and differences between it and
operative cardiopulmonary bypass are noted.
Background
The beginning of extracorporeal circulation dates
back to 1936 when John Gibbon first developed
a means by which haemodynamic and pulmonary
support could be delivered using external (ex-
tracorporeal) circulating devices. His first heart-
lung machine consisted of a roller pump, which
provided a mechanism for delivering flow, and
a vertically-oriented revolving cylinder, over
which blood would drip.2 Oxygenation occurred
through the direct exposure of red blood cells to
ambient oxygen. Heparin, discovered by McLean
in 1917 and introduced into clinical practice in
1938,3 permitted blood to be delivered through
artificial conduits without clotting. With the
advent of these basic components, the technique
of extracorporeal circulation began to evolve.
The design of the original oxygenators was not
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suitable for the prolonged support provided by
ECMO, since the direct exposure of blood cells
to air or oxygen required by these oxygenators
caused extensive protein denaturation after
several hours. 4,5 Changes in oxygenator design,
however, eventually occurred. In 1956, Clowes
introduced a plastic membrane into his
oxygenator in order to separate the blood and
gas phases,6 6 and Kammermeyer, in 1957,
discovered that gas exchange could occur more
effectively if a thin membrane of
dimethlysiloxane, commonly known as silicone
rubber, was used instead of plastic? In the early
1960s, Kolobow incorporated both these features
into his ’membrane lung’, which permitted blood
and oxygen to flow separately between thin layers
of silastic-coated Dacron and fibre-glass screens.8
The layers of silicone membranes were spirally
wrapped to form a compact unit resembling the
appearance of modern membrane lungs.
Eliminating the direct interface between blood
and oxygen significantly decreased protein
denaturation and permitted prolonged support
with an external oxygenator. Kolobow tested his
lung in lambs and was able to support them on
partial bypass for up to seven days.9
The first successful case of prolonged
extracorporeal support in humans was reported
by Hill in 1972.1° Several other investigators
began applying this new method of pulmonary
support to moribund adults with respiratory
failure.11,12 In order to assess the efficacy of
ECMO, a prospective randomized trial, funded
by the National Institutes of Health, was
instituted to compare survival in adults with
respiratory insufficiency treated by conventional
therapy to those treated with ECMO. 13 Although
the survival rate with ECMO was 9.5% compared
to 8.3% using traditional management, 14 the lack
of a statistically significant difference between
the two survival rates dampened enthusiasm to
pursue further clinical trials in adults. A
retrospective assessment of these results
suggested that the entrance criteria into the study
were too stringent, as most patients who were
enrolled already had permanent and irreversible
lung injury, caused either by the disease process
itself or by prolonged aggressive ventilatory
support 15 - the benefits of ECMO could not be
realized in such circumstances. Continued
research into the clinical application of ECMO
did persist, however, with a new focus on cardiac
and respiratory support in neonates.
Most forms of neonatal pulmonary pathology
and subsequent respiratory insufficiency follow a
clinical course that lends itself readily to support
with ECMO. A common denominator seen in
neonatal pulmonary failure is a condition known
as persistent fetal circulation (PFC). PFC denotes
an abnormal shunting of deoxygenated blood
from the right to the left heart across a patent
ductus arteriosus or foramen ovale. PFC may
result from deficiencies in alveolar surfactant,
hyper-reactivity of the pulmonary vasculature,
infection or from a toxic insult such as meconium
or blood aspiration. Unlike several adult
pulmonary diseases, PFC is a reversible
phenomenon. The goal, therefore, in using
ECMO in the neonatal population is to provide
temporary respiratory support during the acute
disease process until the PFC is resolved.
Conventional mechanical ventilation is often
inadequate in providing sufficient oxygenation
during the acute phase. The high ventilatory
associated pressures cause significant barotrauma
with immediate and long-term pulmonary -
morbidity. ECMO obviates the need for such
high ventilatory pressures during the acute
disease process and enables adequate
oxygenation to occur without the attendant
barotrauma. When the acute process resolves,
ECMO can be discontinued and ventilation
resumed at reasonable pressure levels.
In 1975, Bartlett et al. reported the first
neonatal survivor of acute respiratory
insufficiency from meconium aspiration in which
ECMO was used. 16 With this encouraging report,
two prospective randomized trials were launched
which ultimately demonstrated the safety,
efficacy and benefit of ECMO support in neonatal
respiratory failure. 17,18
Presently, over 3300 patients have been treated
with ECMO with a neonatal survival rate of
83% .19 Using previously established criteria,
survival without ECMO would be only about
15%.2°-22 The present applications of ECMO
continue to expand and include postoperative
cardiac support in the paediatric population,
perioperative support in cardiac transplantation
and paediatric and adult respiratory support




The circuitry of ECMO represents a simplified
modification of that used during cardiopulmonary
bypass. Certain obvious differences are readily
apparent to the perfusionist who is unfamiliar
with an ECMO circuit: perfusion and siphon
cannulae do not exit the chest through a
sternotomy; there is no reservoir to transfuse or
haemodeplete a patient; no coronary suction
device exists; blood filters are eliminated;
stagnant areas are avoided; and servoregulation
of pump flow is present. Management issues in
caring for the patient on bypass are likewise
different: the level of anticoagulation appears
unusually low; variations in pump flow rates do
not universally improve tissue perfusion;
ventilatory support is titrated with and not
completely replaced by bypass; patients are
awake and moving about; and care is provided
for several days rather than several hours. To
present the significance of the differences
between ECMO and operative cardiopulmonary
bypass more clearly, each component of the
ECMO circuit will be addressed individually. The
circuitry discussed will apply specifically to
neonates, in whom the majority of the ECMO
cases have been performed. Similar comparisons
also apply to the circuitry for paediatric and adult
patients except that larger cannulae, tubing and
circuit components are used.
Cannulation and the two methods of ECMO
bypass
The most striking initial difference between
ECMO and bypass for cardiac surgery is that
cannulation for ECMO is performed extrathorac-
ically and at the bedside in an intensive care unit.
Perfusion can be accomplished by two forms of
bypass: veno-arterial (VA) or veno-venous
(VV). For either form of bypass, an incision is
made over the target vessels to be cannulated.
In VA bypass, blood is typically siphoned from
a cannula placed through the right internal
jugular vein into the right atrium and is returned
to the patient by a catheter placed through the
right common carotid artery into the aortic arch
after being oxygenated. Venous drainage may
also occur from cannulae placed in the common
femoral or external iliac veins; likewise,
reinfusion can be accomplished through access in
the common femoral or axillary arteries. The
largest-sized catheter that can be introduced into
the target vessel is selected. For neonates,
adequate flow rates (200-500cc/min) and
pressures (100-250mmHg preoxygenator) are
best achieved with a 14 French (F) venous
catheter placed in the right internal jugular vein
and a 10-12F arterial catheter in the right
common carotid artery. The venous catheter has
several side-holes which improve the siphoned
flow within it. Using smaller catheters may cause
insufficient venous drainage or prohibitively high
circuit pressures when flow rates greater than
300cc/min are required. VA bypass in ECMO is
similar physiologically to operative cardiopulmo-
nary bypass in that it provides both cardiac and
pulmonary support for the patient. Increasing the
flow rate through the ECMO circuit will improve
whole-body perfusion, elevate the mean arterial
blood pressure and ensure haemodynamic
stability while providing adequate gas exchange
for the blood.
In VV bypass, blood is both withdrawn from
and reinfused into the central venous system.
Blood is siphoned from the right atrium in a
manner similar to that in VA bypass but is
returned, after being oxygenated, into either the
femoral vein (or other suitably sized peripheral
vein) or back into the right atrium by a newly
designed catheter which has two channels.23 This
double lumen venous catheter, recently
developed and tested at our facility, has a 14F
outer diameter. Its cross-sectional area is divided
disproportionately to enable the larger lumen to
siphon blood from the catheter tip and the smaller
lumen to perfuse through side-holes directed into
the right ventricle. With VV bypass 15-50% of
the central venous blood siphoned into the
ECMO circuit represents recirculated blood from
the venous perfusion cannula. The amount of
recirculation increases as the flow rate increases.
Despite recirculation, sufficient oxygenation of
blood occurs to compensate for the failing lungs.
The primary advantage of VV bypass is that it
avoids ligation of a major artery; sacrificing such
an artery can cause distal ischaemic symptoms if
insufficient collaterals are present. VV bypass is
ideally suited for the patient who has isolated
respiratory failure. Unlike VA bypass, VV bypass
has no role in cardiac surgery. It does not divert
blood away from either the heart or the lung,
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making most modern cardiac surgical procedures
impossible. Furthermore, ’ it provides no
haemodynamic support; adequate tissue
perfusion is entirely dependent upon the patient’s
own cardiac function.
Priming the circuit
While a surgical team cannulates the patient,
ECMO specialists construct and prime the circuit.
The individual steps involved in priming an
ECMO circuit closely parallel those in the
priming of a circuit for operative bypass. The
circuit is first constructed using standard tubing,
connectors and components with the drainage
and infusion tubing leading to a priming reservoir.
Carbon dioxide is flushed through the circuit to
displace atmospheric oxygen and nitrogen. Any
CO, remaining in the circuit after the prime is
completed will dissolve in blood more readily
than will either oxygen or nitrogen, thereby
reducing the chance of inadvertent gas embolism.
Once the circuit is filled with CO~, suction is
applied to the gas phase of the membrane lung,
removing much of the gas within the circuit. The
ECMO specialist then adds, sequentially to the
circuit, a balanced crystalloid prime, albumin to
coat the prosthetic surfaces and decrease platelet
and fibrinogen adherence and, finally, blood to
displace the crystalloid. A neonatal circuit
contains approximately 500cc of volume, which
-- is considerably more than the blood volume of
a neonate. Initiating bypass without a blood
prime would cause significant haemodilution and
haemodynamic instability. Adjustments of the
, primed blood’s pH and temperature frequently
need to be made before connecting the patient
to the circuit.
Blood saturation monitoring
After the vessels are cannulated, the catheters
are connected to the polyvinylchloride (PVC)
tubing of the primed ECMO circuit. Figure 1
depicts the individual components of the system
diagrammatically. As blood is siphoned from the
right atrium, it drains past a fibre-optic probe
into a bladder reservoir. The fibre-optic probe is
attached to the circuit through a Tuohy-Borst
connector and is in constant contact with the
flowing blood. This probe provides a continuous
on-line measurement of the saturation of blood
being siphoned from the right atrium. In VA
bypass this value actually represents the patient’s
mixed venous saturation. Variance in the mixed
venous saturation reflects changes in the
haematocrit, haemoglobin saturation, bypass flow
rate, the patient’s own cardiac output or the rate
of tissue metabolism. In VV bypass the saturation
value is of less importance as an absolute number
but is helpful when considered as a trending
value. Changes in the saturation during VV
bypass are likely to reflect similar changes
observed in VA bypass, but the magnitude of
these changes may be masked because of
recirculation effects.
Servoregulation
The bladder reservoir is the component of the
circuit that lies in the most dependent portion,
since siphoned flow to it is determined by its
distance from the right atrium. The reservoir is
made of silicone rubber which permits small
changes in its volume to occur. The reservoir
servoregulates a double occlusion roller pump
which drives flow within the system. A pressure
sensor which is in continuous contact with the
elastic wall monitors the bladder volume. When
the volume falls and the bladder walls begin to
collapse, a pressure change is detected and power
to the roller pump is temporarily interrupted,
stopping flow. Continuous suctioning by the roller
pump against inadequate venous return would
cause haemolysis, cavitation of dissolved oxygen
and damage to the endothelium at the side-holes
of the venous catheter. A momentary
interruption of flow permits additional blood to
enter the bladder reservoir, replenish its volume
and displace the pressure sensor of the reservoir
back to its normal position. Power returns to the
roller pump which restores flow in the circuit.
Adjustments in flow rate or catheter position can
then be made to ensure continuous,
uninterrupted flow. The servoregulation between
the bladder and the roller pump replaces the
open or bag blood reservoir used during bypass
for cardiac surgery. Removing this component
eliminates any direct interface between blood and
ambient gases and reduces protein denaturation
during prolonged bypass. Maintaining a closed
system further decreases the possibility of
inadvertent air embolism.
Other centres employ different means of
controlling ECMO bypass flow. Shiley (Irvine,
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California) has introduced a system in which
changes in luminal pressure control pump flow:
a sensitive transducer on the venous end detects
pressure drops below a preset level; as the
pressure falls, the transducer effects a decrease
in the pump’s flow rate and therefore causes a
rise in venous pressure towards a baseline value.
To prevent excessive pressurization within the
circuit, transducers placed on the high-pressure
side of the pump can slow down the flow rate
in a similar fashion. In Europe, a unique flow
device called the Rhone-Poulenc pump (Paris,
France) does not require an external device to
servoregulate its drive mechanism. This pump
contains three vertical posts around which a
distensible silastic tube connected in series with
the ECMO circuit is stretched. Flow is delivered
when the rotating posts pinch off segments of
the tubing and deliver the contained blood. If
the rate of blood siphoning cannot keep pace
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with the rate of attempted delivery, the amount
of blood contained between each pinched off
segment of raceway tubing will fall, decreasing
the effective blood flow. When venous pressure
rises and the siphon rate increases, blood flow
within the circuit will increase.24
Pumps
In most ECMO centres, roller pumps rather
than centrifugal pumps are used to deliver flow.
Roller pumps offer several advantages, making
them more suitable for long-term bypass. Studies
performed in our laboratory with different
centrifugal pumps and our standard double
occlusion roller pump demonstrate significantly
less haemolysis with the latter pumps In
addition, the mechanics of a centrifugal pump
are not as tightly responsive to servoregulation
as those of a roller pump. When power to a
roller pump is interrupted, as occurs with
insufficient venous return, the heads of the pump
stop turning and flow in the circuit ceases
immediately. The rotating head of a centrifugal
pump, on the other hand, will continue to spin
for a brief time after servoregulation interrupts
its power. The negative pressure generated
(relative to atmospheric pressure) can lead to gas
cavitation, vessel endothelial damage and
- additional haemolysis from erythrocyte
deformation. Other features of a roller pump’s
simple design make it a preferred flow-delivering
device: it contains no valves, chambers or
complex moving parts to malfunction; flow rate
can be directly calculated from the RPM of the
pump head, obviating the need for an in-line flow
probe; the chamber in contact with the roller
pump is a component of the bypass circuit, i.e.
the PVC tubing; and it does not require cleaning,
replacement or adjustments.’ Disadvantages of
roller pumps include tubing rupture in the
raceway, gas embolization and over-pressurizing
the circuit. Flow is calculated from RPM of a
roller pump; if the raceway tubing deforms during
prolonged bypass, the calculated flow will be
inaccurate.
Tubing, raceway and compliance
The tubing used in the raceway of the roller
pump is different from that in the remainder of
the circuit. A neonatal circuit is made of PVC
tubing with a wall thickness of 1/16 inch. In the
past, when this tubing was used throughout the
circuit, raceway rupture was a not uncommon
event and the raceway tubing would be regularly
’walked’ or advanced to avoid the continuous
stress placed by the roller head on the raceway.
This problem is now averted with the use of more
durable PVC tubing (’Supertygon’@, Norton
Plastics, Akron, Ohio). The bypass circuitry used
during cardiac surgery does not need to
incorporate ’Supertygon’@ tubing because the
duration of bypass is relatively short.
An ECMO circuit contains a relatively fixed
volume of blood, the silicone bladder being the
only element of volume variability. Volume
cannot be transferred from a patient to a
component in an ECMO circuit as can be done
with a reservoir in an operative bypass circuit.
The patient is the only compliant component of
an ECMO circuit, and excess volume in this
closed system is seen as third-spaced oedema and
intravascular volume expansion in the patient.
Reduction in the total fluid requires diuresis,
haemofiltration or actually removing blood from
the circuit.
Oxygenators
After leaving the roller pump, blood flows
under positive pressure to the membrane lung.
At the University of Michigan Medical Center
(UMMC) we use Sci-Med (Minneapolis,
Minnesota) lungs routinely. Neonates require
lung sizes ranging from 0.4 to 0.8m2, children
from 1.5 to 2.5m2 and adults from 3.5 to 4.5m2.
Selection of a properly sized membrane lung
requires knowledge of its blood and gas flow
properties. As the surface area of a membrane
lung increases, the pressure drop across the lung
becomes less for any given flow rate. The internal
resistance of each lung is a function of both its
surface area and the volume in which it is
wrapped. If high flow rates are anticipated a
larger lung should be incorporated into the
circuit. Excessively high circuit pressures
(>400mmHg preoxygenator) may cause circuit
rupture or premature lung failure. In addition to
internal resistance, each lung is characterized by
its ability to transfer gases at specific blood flow
rates. The ’rated flow’ of a lung describes the
maximal flow at which blood, entering a lung
with a saturation of 75%, can exit the lung at
95% saturation; selection of an appropriately
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sized lung, therefore, requires an estimate of the
anticipated flow through it. Cardiac outputs in
resting patients range from 70-90cc/kg/min in
adults, 80-100cc/kg/min in children and 120-
170cc/kg/min in neonates. Lungs incorporated
into bypass circuits need to transfer both 02 and
C02 adequately at the anticipated flow rates
required by the patient.
Oxygen, carbogen or a mixture of the two is
ventilated through the membrane lung in a
counter-current fashion at a rate sufficient to
maintain the postoxygenator PC02 below
40mmHg. Carbogen is commonly used in the
neonatal population. At lower blood flow rates
the removal of C02 from the blood is more
effective than is the transfer of oxygen to the
blood. A marked respiratory alkalosis can occur
if pure oxygen is ventilated through the
membrane lung. When carbogen is added the
resulting PC02 will rise, but not by more than
40mmHg. When pure carbogen cannot reduce
the PC02 of exiting blood sufficiently and pure
oxygen causes excessive C02 removal, oxygen
and carbogen can be blended together in the
ventilating gas to create a mixture that produces
a normal arterial PC02’
Several monitoring features are attached to
components of the membrane lung. Pressure
transducers connected immediately before and
after the oxygenator provide a continuous
assessment of oxygenator function in terms of its
blood flow characteristics. A high pressure drop
across the membrane lung indicates impending
lung failure and a need for replacement. High
postoxygenator pressures warn of prohibitively
high blood flow rates through a narrow reinfusion
catheter or of a kink within the system. When
the rate of gas flow through a membrane lung is
high, over-pressurization of the gas phase and
subsequent gas embolization could occur.
Pressure pop-off valves are therefore included in
the sweep gas line to guard against inadvertent
and excessive pressure build up.
Heat exchangers
After leaving the oxygenator, blood flows
through a separate heat exchanger, where it is
warmed to 37°C. The heat exchanger used at
UMMC is made by Sci-Med and is connected to
a heating unit made by Seabrook (Cincinnati,
Ohio). Unlike the circuits for bypass surgery, the
heat exchanger in an ECMO circuit lies in series
after the membrane lung. Exposure of the blood
tubing and circuit components to ambient
temperature causes rapid cooling of the patient,
especially the neonate who lacks mature
thermogenesis capabilities. A membrane lung
with its large surface area will cause the greatest
temperature drop in the circuit. High gas flow
rates through the membrane lung will further
accentuate this temperature drop. Placing the
heat exchanger immediately after the membrane
lung will warm the blood just before it returns
to the patient. This design ensures that minimal
heat loss will occur between the heat exchanger
and the patient. The theoretical problem of
generating oxygen bubbles by heating saturated
blood has not proved to be a significant
consideration.
The PVC tubing connecting the membrane lung
to the heat exchanger lies at the highest part of
the bypass circuit, arching between these two
components. This area serves as the last bubble
trap within the circuit and helps to minimize the
risks of gas embolism.
Bridge
From the heat exchanger, blood travels directly
to the reinfusion cannula. A bridge of PVC tubing
connects the arterial and venous lines. Flow
through the bridge is prevented by a tubing clamp’
which occludes its lumen. Periodic flushing of
the bridge by releasing the clamp avoids
prolonged periods of blood stagnation and
reduces the incidence of clot formation. This
bridge permits recirculation of blood within the
ECMO circuit when the patient-connecting lines
are clamped during cannulation and trials off
bypass.
Managing a patient on ECMO
Typically, the care of a patient on bypass requires
two persons, a nurse and an ECMO specialist.
Nurses generally perform bedside patient care,
dressing changes and medicine acquisition.
ECMO specialists are trained nurses, respiratory
technicians, perfusionists or physicians who have
completed an extensive course dealing with the
physiology and technology of prolonged
extracorporeal support.26 Their course work is
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supplemented with hours of bedside instruction.
ECMO specialists maintain circuit integrity,
administer medication and blood products into
the circuit and regulate the blood flow rate. All
interventions are made within the boundaries of
prewritten orders provided by a physician.
Numerous details are addressed by the ECMO
specialist, the most time-consuming of which is
an accurate record of fluid balance. The bedside
flow sheet details an hourly and cumulative fluid
balance, including the volume of blood sampled,
volume of medications given and fluid losses
through the dressing, chest tubes and drains. This
balance, along with daily weights, provides
valuable information in assessing a patient’s
ability to wean from bypass.
Significant differences exist in the level of
anticoagulation needed for ECMO compared to
bypass for cardiac surgery. The initial loading
dose of heparin is only 100U/kg. Thereafter,
heparin is administered (usually 30-60U/kg/hr)
to maintain the activated clotting time (ACT)
between 180-200 seconds under normal
circumstances. The ACT is measured hourly.
Diligent attention to the urine output, volume of
plasma transfused and rate of heparin infusion
permits very precise control of the ACT. The
infinite ACTs maintained during operative car-
-- diopulmonary bypass are not needed while on
ECMO and would greatly increase the incidence
of bleeding complications. ACTs for ECMO were
formerly maintained near 250 seconds, but as our
experience has evolved we have progressively
reduced ACTs to present levels without
developing any new clotting problems.
Occasionally, because of extraordinary clinical
circumstances, ECMO bypass has been run with
little or no heparinization for periods longer than
48 hours. If flow rates are great enough, clotting
problems do not usually occur. ,
Platelets are administered as necessary to
maintain a level greater than 100 000/mm3.
Because of their adherence to the membranes,
platelets are infused into the circuit after the
oxygenator. Elimination of filters on the infusion
side of the circuit helps to prevent the
consumptive thrombocytopenia seen during
bypass.
The flow rates used during bypass depend upon
the type of bypass being employed and the
reasons for instituting bypass. VA bypass
provides both cardiac and pulmonary support.
With neonates, full cardiac output is achieved
with flows approaching 120-170cc/kg/min. At
these levels the pulse contour of the arterial wave
form will be markedly dampened. The adequacy
of the flow is measured physiologically by the
patient’s mean arterial blood pressure, urine
output and mixed venous saturation. Mean
arterial blood pressure (MAP) can be affected
by administering volume to ensure adequate
vascular capacitance and by regulating pump
blood flow to act against a patient’s vascular
resistance. Correct selection of the proper
intervention depends upon the information
available to the physician or ECMO specialist at
the patient’s bedside. Urine output is traditionally
regarded as the best physiological parameter of
adequate perfusion. Unfortunately, it is not
always reliable early in the patient’s course
on bypass. Not infrequently, patients are
placed on ECMO after a prolonged period
of hypotension, anoxia or both during which
attempts at more conventional management
have failed. Renal tubular damage occurs
and can cause a low urine output despite
apparently adequate flow rates and mean arterial
pressures.
Mixed venous saturation (SV02) at the UMMC
is the parameter in VA bypass most commonly
used to assess the adequacy of flow and total
oxygen delivery. In healthy adults the SV02 is
approximately 75% at a resting state. Given an
arterial saturation near 100%, oxygen delivery is
four times greater than oxygen consumption. If
bypass is able to achieve near 100% arterial
oxygen saturation in the patient, flow rates will
be adjusted to maintain an SV02 of
approximately 75%. A fall in SV02 will reflect
either a decrease in haematocrit, arterial
haemoglobin saturation or total cardiac output
or an increase in tissue metabolism. In practice,
several variables are assessed and treated when
a low SV02 occurs: first, blood should be
transfused if the haematocrit is less than 45%;
secondly, the function and adequacy of the size
of the oxygenator must be addressed, especially
if the postoxygenator haemoglobin saturation is
less than 100%; thirdly, the bypass flow rate may
need to be increased if the first two variables are
optimized; and fourthly, sedation, paralysis, or
modest cooling of the patient should be instituted
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if the patient is hypermetabolic.
In VV bypass, management issues are slightly
different. The primary goal of VV bypass is to
permit a reduction of the high pressures delivered
by mechanical ventilators by oxygenating the
central venous blood. Bypass flow rates are
increased to effect an arterial haemoglobin
saturation greater than 90% if possible. Unlike
VA bypass, VV bypass provides no direct
improvement in cardiac output. The saturation
of siphoned venous blood will not represent the
true SVO, because of recirculation effects, and
the adequacy of tissue perfusion is therefore
assessed based on clinical and laboratory
observations. Usual clinical measures of tissue
perfusion include urine output, time for capillary
refill, quality of peripheral pulses and blood
pressure, while comparable biochemical measures
include pH, lactate levels, creatinine, etc.
Patients will retain the typical wave contour of
arterial blood pressure which will not be
dampened as in VA bypass. Enhancing cardiac
output in patients on VV bypass requires the
administration of inotropic and chronotropic
agents. The function of the patient’s own heart
is the sole determinant of cardiac output, and
changes in bypass flow will not directly alter
cardiac function or tissue perfusion.
Airway management during bypass requires
individualized attention based upon a patient’s
specific disease process and the level of ECMO
support provided. When full bypass flows are
reached, the amount of ventilator support can
be reduced to ’rest settings’. In the neonate these
generally include a peak inspiratory pressure of
20cm H20, a positive end-expiratory pressure
(PEEP) of 4cm H20, respiratory rate of 10-20
breaths per minute and an inspired Fio2 of 30%.
Reducing airway pressures avoids barotrauma
and reduces the incidence of late development
of bronchopulmonary dysplasia. Other means of
airway management are possible and may include
extubation, low continuous positive airway
pressure (CPAP) in patients with a bronchopul-
monary fistua, high PEEP or frequent pulmonary
lavages.
Complications
Bleeding is the most common complication seen
in patients on ECMO. 27 Bleeding has been
reported from operative sites, mucous
membranes, stomach and distal gastrointestinal
tract, and miscellaneous locations within the
cranium, pleura, pericardium or
retroperitoneum. Conservative techniques used
to manage bleeding complications include
maintaining the platelet count at above 150 000/
mm3 and lowering the ACT levels. ACTs have
been lowered into the 120-140 second range
without apparent clotting problems. On rare
occasions, if flow rates are high, heparinization
can be discontinued with caution. All surgical
sites should be re-explored, and other more
aggressive operative interventions may be
required. If bleeding is severe, ECMO bypass
may need to be temporarily or permanently
discontinued. Of all potential bleeding sites,
intracranial haemorrhage is most serious.
Fortunately it occurs in only 14% of neonates
with gestational ages greater than 35 weeks.28
Circuit-related problems are occurring less
frequently as modifications in design and better-
tested equipment are incorporated. Technical
problems include oxygenator failure, roller pump
or heat exchanger malfunction, raceway or other
tubing rupture and air leakage into the circuit.
Most of these complications cause temporary
physiological instability while the circuit
components are changed and rarely cause any
permanent morbidity.
Other complications seen include tension
pneumothorax, pericardial tamponade, seizures
and organ failure; surprisingly, catheter-related
sepsis is vanishingly rare.
Weaning the patient off ECMO 
&dquo;°°’
The duration of ECMO support in the neonatal
population ranges from four to seven days
(average 126 hours). The longest length of time
spent on ECMO at UMMC as of January 1990
is 27 days for a child with severe viral respiratory
illness; he subsequently recovered and suffers no
apparent long-term sequelae.
After cannulation, the majority of ECMO
patients are allowed to stabilize for 24-48 hours
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at a flow rate sufficient to provide adequate
oxygenation. If patients receive large volumes of
fluid during their resuscitation prior to initiating
ECMO, aggressive diuresis with frusemide or
mannitol is begun. Haemofiltration is used to
remove excess volume when the kidneys are
unresponsive to diuretics.
Signs of improvement are assessed daily while
on ECMO bypass. These include parenchymal
clearing on serial chest X-rays, rising pulmonary
compliance, increasing end-expiratory CO,
production measured in the airway, rising pO,
in the patient’s arterial blood gases (ABG) in
addition to mobilization of third-spaced fluid,
rising SVOz or MAP. With VA bypass the flow
rate is progressively reduced to maintain MAP,
SV02’ and ABGs at acceptable levels. When it
appears that a patient can support himself
haemodynamically and maintain adequate
oxygenation with minimal ventilator support, a
trial off bypass is attempted. This necessitates
clamping the patient-connecting lines and
removing the clamp on the bridge to allow
recirculation. Ventilatory support needs to be
increased from ’rest settings’ to those sufficient
to provide adequate pulmonary gas exchange.
Decannulation can proceed if the patient remains
stable for 45-60 minutes.
In theory, weaning off VV bypass is simpler
since VV bypass provides no cardiac support.
- During a course on VV bypass the ECMO flow
rate is progressively reduced as pulmonary
function improves. This improvement is
evidenced by a rising arterial haemoglobin
saturation seen on a transcutaneous sensor. The
bypass flow rate can then be decreased to
maintain the arterial haemoglobin saturation
greater than a suitable minimum value, usually
90%. When the flow rate reaches a low level
(30cc/kg/min), a trial off bypass can be attempted.
This trial involves removing the ventilating gas
line from the membrane lung and capping off
the gas inlet and outlet ports. Blood is still
siphoned from and returned to the patient, but
no gas exchange occurs. The bridge remains
clamped. The settings on the ventilator are
increased to levels commensurate with
physiological support. A successful trial off
bypass for 30-45 minutes demonstrates sufficient
lung recovery to permit decannulation.
Summary
The technology of ECMO support continues to
evolve. New advances presently in development
include the manufacturing of paediatric- and
adult-sized double lumen catheters, the use of
heparin-coated tubing and the automation of
bedside ECMO control. As the applications of
ECMO branch deeper into the area of cardiac
transplantation and support, the interface
between the ECMO specialist and perfusionist
will become less distinct. Both the ECMO
specialist and perfusionist will provide a
continuum of patient care, spanning preoperative
cannulation in the intensive care unit,
intraoperative management during corrective
cardiac surgery and postoperative cardiac
recovery back in the ICU. As bypass technology
advances and its applications broaden, the
challenges faced by perfusionists will continue to
grow.
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